AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...
Investor's Business Daily on MSN5d
AbbVie Surges 8% As Immunology Powerhouses Skyrizi And Rinvoq Continue To DominateAbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...
Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in ...
Zacks.com on MSN1d
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...
In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy over Humira and other currently leading treatment options, which should support combined annual sales of ...
Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $205 and keeps a Buy rating on the shares. AbbVie repeated its usual beat in ...
AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...
Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $220 from $218 and keeps an Outperform rating on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback